Acute Lymphocytic Leukemia Pipeline 2026: Therapies and Clinical Trials Assessment

DelveInsight's report provides comprehensive insights into the present clinical development scenario and growth prospects across the Acute Lymphocytic Leukemia market.

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

According to DelveInsight's assessment, the Acute Lymphocytic Leukemia pipeline globally constitutes 120+ key companies continuously working towards developing 125+ Acute Lymphocytic Leukemia treatment therapies. The report provides detailed analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments for the Acute Lymphocytic Leukemia market.

Why it matters

The Acute Lymphocytic Leukemia pipeline report highlights the growing focus on developing novel therapies to address the unmet needs in the Acute Lymphocytic Leukemia treatment landscape. The report analyzes the current pipeline of Acute Lymphocytic Leukemia therapies and the potential impact of emerging treatments on the market.

The details

The Acute Lymphocytic Leukemia Pipeline Insight, 2026 report by DelveInsight provides a comprehensive analysis of the present clinical development scenario and growth prospects across the Acute Lymphocytic Leukemia market. The report covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisitions, funding, designations, and other product-related details.

  • In February 2026, AstraZeneca announced that CALQUENCE (acalabrutinib) in combination with Venetoclax has received approval in the United States as the first all-oral, fixed-duration treatment regimen for adult patients with Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL).
  • In May 2025, Sellas Life Sciences has administered the first pediatric dose of SLS009 (tambiciclib) in its multi-center Phase II trial for relapsed/refractory (r/r) acute myeloid leukemia (AML).
  • In December 2024, The first interim analysis of the Phase III AALL1731 trial demonstrated that adding Blincyto (blinatumomab; Amgen) to chemotherapy significantly increased three-year disease-free survival (DFS) in newly diagnosed pediatric patients with standard-risk (SR) B-cell acute lymphoblastic leukemia (B-ALL).
  • In December 2024, Groundbreaking results from a major clinical trial, partially supported by the St. Baldrick's Foundation, were revealed at the 66th Annual Meeting of the American Society of Hematology (ASH) in San Diego, Calif.
  • In November 2024, The U.S. Food and Drug Administration (FDA) has approved obecabtagene autoleucel (Aucatzyl) for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

The players

Nanjing Bioheng Biotech

A Chinese biotechnology company developing therapies for Acute Lymphocytic Leukemia, including the investigational drug CTA30X.

Apamistamab Actinium Pharmaceuticals

A U.S. biopharmaceutical company focused on developing targeted radiotherapies, including the Acute Lymphocytic Leukemia therapy 131-I.

Cellectis S.A.

A French biopharmaceutical company developing the Acute Lymphocytic Leukemia therapy UCART22, a gene-edited allogeneic CAR T-cell product candidate.

Autolus Limited

A U.K. biopharmaceutical company developing the Acute Lymphocytic Leukemia therapy AUTO1, a next-generation CAR T-cell product candidate.

Takara Bio Inc.

A Japanese biotechnology company developing the Acute Lymphocytic Leukemia therapy TBI-1501.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

The Acute Lymphocytic Leukemia pipeline report highlights the significant progress being made in the development of novel therapies to address the unmet needs in Acute Lymphocytic Leukemia treatment. The report analyzes the current pipeline of Acute Lymphocytic Leukemia therapies and the potential impact of emerging treatments on the market, providing valuable insights for healthcare stakeholders.